Study Details
Semaglutide and Adult Metabolic Health
(IRB#: IRB_00181932)
Semaglutide (known as Ozempic and Wegovy) is a type 2 diabetes and/or weight loss drug. Semaglutide is helpful for most people to lose weight, but it is unknown why some people do not experience weight loss or only lose limited weight with semaglutide. It is also unknown if certain people are more likely than others to regain weight if they stop taking semaglutide. This study will see how semaglutide impacts metabolism and the ability to maintain long-term weight loss. The information may improve diabetes and weight management care with semaglutide. Participants in the study will all use the drug semaglutide along with regular medical care. Being in the study requires attending regular in-person medical care visits along with 2 study visits for over 6 to 8 months. Medical tests will be done during the study to track the health of participants.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- 18 to 65 years old
- Must have established care with a physician at the University of Utah Health for either diabetes or weight management
- People with type 2 diabetes must have an HbA1c between 7 and 10%
- Must not have taken the first dose semaglutide at the time of study enrollment
- Able to attend in-person visits to the medical clinic
Exclusion Criteria
- Use of any GLP-1 medication within 180 days of study enrollment
Will I be paid for my time?
Yes
IRB#: IRB_00181932
PI: KATSUHIKO FUNAI
Department: PHYSICAL THERAPY - COH
Approval Date: 2025-01-22 07:00:00
Study Categories: Diabetes Studies, Weight Loss Studies
Specialties: Endocrinology & Metabolism
I am Interested